Sanofi and AstraZeneca's preventative treatment for respiratory syncytial virus (RSV) has been recommended for use by an independent health expert body advising the U.S. Centers for Disease Control and Prevention (CDC).
The treatment, named Beyfortus, contains a monoclonal antibody and is now recommended for use in all infants below 8 months of age as part of their routine immunizations, according to Sanofi. The CDC committee, known as the Advisory Committee on Immunization Practices, also recommends its use in children up to 19 months of age who are at an increased risk of catching the virus.
This recommendation comes after the early approval of the drug by the U.S. Food and Drug Administration in mid-July, marking a significant milestone as the first drug approved for RSV in infants and children. RSV is the primary cause of hospitalization among infants in the U.S., and it is responsible for the deaths of up to 300 children under the age of 5 each year.